Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PPA on prime time

This article was originally published in The Tan Sheet

Executive Summary

Phenylpropanolamine safety concerns were focus of Fox Television's March 24 episode of "Beverly Hills 90210," which centered on a 17 year-old girl's abuse of an OTC diet aid containing the ingredient. The episode showed the character ingesting 2-3 times the regular dose of the PPA-containing product and starving herself until she collapses and is hospitalized. A refrain in the story was: "the product is available OTC and therefore must be safe." Industry has already stepped up label warnings under a voluntary agreement with FDA last fall. New labeling warns that PPA-containing diet aids should not be consumed by individuals under 18 years old and that the recommended dosage should not be exceeded. FDA currently is evaluating a case control study submitted by NDMA aimed at settling the issue of PPA safety in weight loss products ("The Tan Sheet" March 15, p. 8). An FDAer told FDLI March 25 that the agency is interested in meeting with NDMA sometime in April to discuss the study.

You may also be interested in...



Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

People In Brief

Perrigo promotes in pricing, planning

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS081275

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel